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Abstract: Perinatal hypoxic-ischemic encephalopathy (HIE) is the leading cause of mortality and
morbidity in neonates, with survivors suffering significant neurological sequelae including cerebral
palsy, epilepsy, intellectual disability and autism spectrum disorders. While hypothermia is used
clinically to reduce neurological injury following HIE, it is only used for term infants (>36 weeks
gestation) in tertiary hospitals and improves outcomes in only 30% of patients. For these reasons,
a more effective and easily administrable pharmacological therapeutic agent, that can be used
in combination with hypothermia or alone when hypothermia cannot be applied, is urgently
needed to treat pre-term (≤36 weeks gestation) and term infants suffering HIE. Several recent
studies have demonstrated that cationic arginine-rich peptides (CARPs), which include many
cell-penetrating peptides [CPPs; e.g., transactivator of transcription (TAT) and poly-arginine-9 (R9;
9-mer of arginine)], possess intrinsic neuroprotective properties. For example, we have demonstrated
that poly-arginine-18 (R18; 18-mer of arginine) and its D-enantiomer (R18D) are neuroprotective
in vitro following neuronal excitotoxicity, and in vivo following perinatal hypoxia-ischemia (HI).
In this paper, we review studies that have used CARPs and other peptides, including putative
neuroprotective peptides fused to TAT, in animal models of perinatal HIE. We critically evaluate the
evidence that supports our hypothesis that CARP neuroprotection is mediated by peptide arginine
content and positive charge and that CARPs represent a novel potential therapeutic for HIE.
Keywords: hypoxic-ischemic encephalopathy; hypoxia-ischemia; birth asphyxia; neuroprotection;
cationic arginine-rich peptides; animal models

1. Introduction
Perinatal hypoxic-ischemic encephalopathy (HIE; also referred to as birth asphyxia) remains
the leading cause of neonatal mortality and morbidity, with an incidence in developed nations
of 2–6 and 7 in every 1000 live term (>36 weeks gestation) and pre-term (≤36 weeks gestation)
births, respectively [1,2]. The incidence is even higher in developing countries, with rates of up to
30 per 1000 live full-term births [3,4]. Of the individuals affected by HIE, 15–20% will die in the
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postnatal period, and an additional 25% will develop severe and permanent neurological sequela.
Each year, HIE accounts for up to 1.2 million deaths [5] and some form of central nervous system
(CNS) dysfunction in an estimated 1.15 million neonates [6] such as cerebral palsy, epilepsy, global
developmental delay, intellectual disability, behavioral disorders and autism spectrum disorders [7–11].
While hypothermia is used as a therapeutic intervention to minimize brain injury in neonates suffering
HIE, it only provides beneficial outcomes in approximately 30% of patients and has several limitations
(reviewed below). Therefore, an effective and easily administrable pharmacological therapeutic agent
to improve patient outcomes when used as an adjunct to hypothermia, on its own or when hypothermia
cannot be applied is urgently needed.
In recent years, there has been an increased application of putative neuroprotective peptides
designed to target cyto-damaging or cyto-protective pathways to reduce injury in acute brain disorders
such as HIE. One reason for this interest is the discovery of cell-penetrating peptides (CPPs), allowing
for the delivery of neuroprotective peptides and other molecular cargos (e.g., proteins, nucleic acids and
nanoparticles) across the blood brain barrier (BBB) and into cells within the CNS. Most studies assessing
neuroprotective peptides in animal models of HIE use the cationic arginine-rich CPP, transactivator
of transcription (TAT47–57 YGRKKRRQRRR), as the ‘carrier’ molecule. However, several years ago,
our and other laboratories demonstrated that the TAT peptide has modest intrinsic neuroprotective
properties in its own right [12–17]. We subsequently demonstrated that other cationic arginine-rich
peptides [CARPs; e.g., penetratin, protamine, sodium calcium exchanger inhibitory peptide (XIP),
poly-arginine peptides (e.g., R9, R12 and R18; R indicates amino acid arginine and number indicates
mer)], possess potent neuroprotective properties in both in vitro and animal models of cerebral
ischemia and/or hypoxia [12,18–29], and demonstrated that the arginine content and peptide positive
charge are critical determinants of neuroprotection [19,27,28].
Based on the recent application of cationic CPPs for the delivery of putative neuroprotective
peptides in animal models of HIE and the recent discovery of the intrinsic neuroprotective properties
of CARPs, the objectives of this review are: (i) catalogue studies that have used peptides as
neuroprotective agents in HIE, especially those employing a CPP delivery system; and (ii) to evaluate
the potential neuroprotective effects of both CPP and cargo molecules in terms of their arginine content
and cationic charge, as well as the content of other potentially neuroprotective amino acids such
as tryptophan [29]. We will propose that the neuroprotective properties of most, if not all putative
neuroprotective peptides fused to cationic CPPs are likely to be mediated in a large part by the actions
of the carrier CPP (e.g., TAT) rather than the cargo molecule itself, with potency being further enhanced
according to the amino acid content of the cargo (e.g., number of arginine residues) [19]. In addition,
we will also review the evidence that CARPs have multiple cellular modes of action that underlie their
neuroprotective properties.
First, we provide a brief overview of the major underlying pathophysiological mechanisms
associated with HIE and the application of hypothermia as an acute therapy for the disorder.
2. Pathophysiology of Perinatal Hypoxia-Ischemic Brain Injury
2.1. Initiation of the Pathophysiological Cascade in HIE
The etiology of HIE is associated with a variety of maternal, placental and fetal conditions; all of
which have variable clinical manifestations. These conditions include, but are not limited to, chronic
maternal hypoxia (e.g., chronic utero-placental hypoxia, cardiopulmonary arrest, acute hypotension,
pulmonary embolism or vascular disease), pre-eclampsia, nuchal cord, umbilical cord knotting,
umbilical cord prolapse, shoulder dystocia and premature placental detachment [30]. Perinatal hypoxia
is initiated following an impairment of oxygenated cerebral blood flow (CBF) to the fetus, triggering
responses at both the systemic and cellular levels. The fetal brain is particularly sensitive to a HI
environment, as there is a requirement of a constant supply of energy in the form of ATP, and when
interrupted, excitotoxicity occurs through the uncontrolled release of excitatory neurotransmitters
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such as glutamate; marking the beginning of the ischemic cascade. The acute and downstream
consequences of the ischemic cascade are damaging to neurons and other cells (e.g., glial progenitor
cells and astrocytes) at the cytoplasmic and mitochondrial levels, as well as causing disruption to the
BBB and the activation of inflammatory responses.
2.2. Excitotoxicity
The metabolic rate of the fetal brain is largely determined by the stage of gestational
development [30]. To meet metabolic demands, developing neural tissue metabolizes lactate, ketone
bodies and glucose. When compared to the developed brain, the fetal brain is more adaptable with
respect to energy utilization, thereby increasing its capacity to tolerate hypoxia-ischemia (HI) [31].
However, in the event of a critical depletion of ATP due to prolonged HI, the fetal brain eventually
becomes susceptible to injury.
Following prolonged HI, cellular homeostasis is disrupted due to the depletion of ATP and
failure to maintain ionic gradients, and as a result, neurons depolarize and release glutamate into the
synaptic cleft [32]. High extracellular levels of glutamate cause excitotoxicity in neurons and other cells,
namely glial progenitor cells, that express glutamate receptors (NMDA; N-methyl-D-asparate, AMPA;
α-amino-3-hydroxy-5-methy-4-isoxazolepropionic acid, kainic acid and metabotropic glutamate
receptors), producing a cytotoxic cellular influx of calcium ions [33]. The increased levels of
intracellular calcium in neurons and glial progenitor cells in turn results in the activation of
calcium-dependent proteases, lipases and deoxyribonuclease (DNase), reactive oxygen species (ROS)
production, oxidative stress, cytotoxic edema, mitochondrial dysfunction and the stimulation of
pro-cell death pathways [34–38].
2.3. Oxidative Stress
Oxidative stress plays an important role in the pathophysiology of HIE, as the developing brain
comprises high levels of unsaturated fatty acids susceptible to lipid peroxidation, metals catalyzing free
radical reactions and low concentrations of antioxidants [39]. The resulting heightened sensitivity to
oxidative stress and ROS production following HI causes significant damage to lipids (lipid oxidation),
nucleic acids (DNA degeneration) and proteins (protein oxidation). Sources of ROS following HI
include, the mitochondrial electron transport chain (ETC), NADPH oxidases (NOX), xanthine oxidase
(XO), arachidonic acid (12/15 lipoxygenase), and nitric oxide synthase (NOS). In particular, NOS has
been targeted in HIE, with strategies to ablate or inhibit NOS activity invariably being neuroprotective
in animal models of HIE [40].
2.4. Mitochondrial Dysfunction
Mitochondria have diverse functions, including ATP generation, intracellular calcium regulation,
ROS production, biosynthesis of amino acids, lipids and nucleotides and pro-cell death signaling.
The role of mitochondria in HIE has been extensively reviewed [41–43]. Here we focus on the role of
mitochondria in potentiating secondary pathophysiological cascades contributing to HI. Mitochondria
contribute to secondary brain injury following HI via the regulation of cell death pathways, namely
apoptosis. Cellular apoptosis following HI is activated via both intrinsic (e.g., in response to
mitochondrial dysfunction and damaged DNA) and extrinsic [e.g., in response to cell death receptors
such as Fas and tissue necrosis factor-α (TNF-α)] pathways and involve the release of pro-cell death
proteins from mitochondria.
In cells affected by HI, several processes such as excitotoxicity, ROS production, activation of
p53, DNA damage and altered mitochondrial function can influence the activity of pro-apoptotic
Bcl-2 proteins (e.g., Bid and Bax), resulting in Bax-dependent mitochondrial membrane permeability
transition (MPT) [44,45]. In addition, excessive mitochondrial ROS generation, due to leakage
from the ETC, can oxidize the inner mitochondrial membrane phospholipid, cardiolipin, promoting
mitochondrial membrane permeability transition pore (MPTP) opening and subsequent release of
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cytochrome-c. Cytosolic cytochrome-c, along with deoxyadenosine triphosphate (dATP), interact with
apoptotic protease activating factor-1 (Apaf-1) to form the apoptosome, which cleaves and activates
pro-caspase-9 [46]. Activated caspase-9 in turn activates caspase-3, which is a major proteolytic enzyme
responsible for the ultimate dismantling of cells during apoptotic cell death.
Further alterations to mitochondria, such as mitochondrial outer membrane permeabilization
(MOMP), results in the release other pro-apoptotic factors into the cytosol, including apoptosis-inducing
factor (AIF), endonuclease G (Endo-G), and Smac/DIABLO [47,48]. Translocation of AIF and Endo-G
to the nucleus mediates chromatin fragmentation and Smac/DIABLO interacts with inhibitors of
apoptosis to reduce their actions on activated caspases.
TNF cell death receptor signaling mainly stimulates the extrinsic pathway by activating caspase-8,
which activates other caspases, including caspase-3. While beyond the scope of this review, it is also
important to note that other cell death pathways associated with necrosis, necroptosis, ferroptosis and
autophagy may also be activated in response to HI. These pathways can be activated in response to
one or more cellular disturbances such as calcium influx, mitochondrial dysfunction, cellular energy
depletion, ROS production, TNF receptors cell signaling and other cellular cell signaling pathways
(e.g., adenosine monophosphate-activated protein kinase).
2.5. Inflammation
The inflammatory response following HIE has been extensively reviewed by [49,50] and is
therefore briefly discussed. In the immature brain following HI, an innate immune response occurs
within minutes of the injury [51]. Initially, microglia become activated within the cerebral parenchyma,
followed by a systemic inflammatory response, mediated by the infiltration of circulating monocytes,
neutrophils and T-cells into the brain. Activated microglia develop macrophage-like attributes, such as
phagocytic properties, cytokine production, antigen presentation and matrix metalloproteinase (MMP)
release. The release and activation of MMPs by microglia can compromise BBB integrity, further
promoting the invasion of peripheral leukocytes into the cerebral parenchyma; exacerbating ensuing
cerebral injury. A hallmark of HIE is the aggregation of amoeboid microglia within the periventricular
white matter, resulting in the production of inflammatory cytokines (TNF-α and IL1-β), NO and other
ROS [52]; collectively potentiating the toxic effects of the ischemic cascade in neurons, glial progenitor
cells and the cerebral vasculature.
While astrocytes attempt to provide neuroprotective support to neurons and glia via the release
of glutathione, superoxide dismutase (SOD), extra-synaptic uptake of glutamate and the maintenance
of ion channel gradients, these protective mechanisms can be quickly overrun. As with microglia,
astrocytes become hyper-activated due to the effects of pro-inflammatory cytokines, ROS, and dying
neurons and glia. Activated astrocytes also release pro-inflammatory cytokines (IL-6, TNF-α, IL-1α/β
and INF-γ), further exacerbating HI-induced cell death pathways (e.g., apoptosis). In addition,
astrocytes secrete chemokines that attracts systemic immune cells to infiltrate affected tissue, further
aggravating tissue injury.
3. Current Clinical Treatments: Hypothermia
Hypothermia is considered one of the most effective neuroprotective treatment interventions in
both experimental and clinical settings. While the exact beneficial effects of hypothermia are yet to be
elucidated in HIE, it is known to suppress many of the neuro-damaging events associated with HI
including excitotoxicity, apoptosis, inflammation, oxidative stress and BBB disruption [53].
In HIE, moderate hypothermia (33.5 ◦ C for 72 h), applied within 6 h of birth, improves the
survival and neurodevelopmental outcomes in infants suffering from moderate and severe HIE.
While hypothermia is now considered standard care in the treatment of HIE and is well tolerated in
term infants [54–57], it does not provide complete protection. Of the infants who have moderate or
severe encephalopathy, therapeutic hypothermia was shown to decrease mortality from 40% to 28%,
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while in surviving infants neurological morbidity was reduced from 31% to 19% of infants receiving
therapeutic hypothermia [58].
Importantly, while hypothermia is safe in pre-term infants with necrotising enterocolitis [59],
it has not been adequately evaluated for use in pre-term infants suffering HIE. Information regarding
the safety and efficacy of hypothermia to treat pre-term infants suffering HIE is lacking, although
information may be available in the near future (NCT1793129). In one study, hypothermia in pre-term
infants was associated with higher mortality and increased clinical complications when compared
to term infants [60], although the study did not include a normothermic pre-term control group.
The inadequate application of hypothermia in the pre-term neonate highlights the need for the
development of safer therapeutic interventions in these patients following HI.
In addition, the induction of hypothermia requires specialized equipment, intensive care
monitoring and trained staff, limiting its use to centers that have the facilities and medical personnel
to undertake the procedure. This develops uncertainty regarding the timing, safety and efficacy
of initiating hypothermia in infants before transfer to a centre equipped to deliver hypothermia.
For example, the transfer of infants suffering HIE to a medical centre to provide hypothermia can
exceed 6 h from the time of birth and that attempts of passive cooling during transport can result
in excessive cooling [61]. In light of this, there is an urgent need for the application of an acute
neuroprotective therapy for infants who suffer HIE when hypothermia cannot be applied immediately,
or is not available. In addition, as the incidences of mortality and morbidity are still relatively
high following hypothermia, there is a requirement for additional therapeutic agents, adjuvant to
hypothermia, to further improve outcomes in infants suffering HIE.
4. Neuroprotective Peptides and Their Therapeutic Application in HIE
4.1. Peptide Therapeutics
Peptides represent an important and increasingly popular class of therapeutic agent. To date, over
60 general peptide drugs have been approved in the United States, Europe, and Japan, approximately
140 are in active clinical development and more than 500 peptides are being examined in preclinical
therapeutic studies [62]. Peptides have several beneficial properties over traditional drugs such as high
biological and structural diversity, less toxicity and accumulation in tissue and reduced propensity
to cause drug-drug interactions. The main disadvantage of most peptides is their inability to cross
the BBB and enter cells, which is an important issue if the peptide has an intracellular target and/or
is targeting a CNS disorder. However, as outlined above, the delivery of peptides into the CNS and
into cells can be achieved by using CPPs. For this reason, CPPs have been widely utilized as a carrier
molecule for the delivery of neuroactive compounds into the CNS, including putative neuroprotective
peptides. Below we review experimental studies that have used neuroprotective peptides in HIE
models, including putative neuroprotective peptides fused to a CPP. First, we summarize findings
from our own and other laboratories highlighting the intrinsic neuroprotective properties of CARPs.
4.2. CARPs Are Intrinsically Neuroprotective
An early study by Ferrer-Montiel et al. [63], demonstrated that cationic arginine-rich hexapeptides
(i.e. containing 2–6 arginine residues; net charge +3–+7; e.g., RRRRRR-NH2 ) were neuroprotective
in an in vitro hippocampal neuronal NMDA excitotoxic model. These findings were in line with
subsequent studies in our and other laboratories, demonstrating that the CPP TAT (YGRKKRRQRRR;
net charge +8) possesses intrinsic neuroprotective properties following in vitro glutamic acid
excitotoxicity and oxygen glucose deprivation (OGD), as well as in vivo following excitotoxicity and
cerebral ischemia in rats [13–16,64,65]. We subsequently demonstrated that in an in vitro cortical
neuronal excitotoxic model, the CPPs poly-arginine-9 (RRRRRRRRR-NH2 ; net charge +10) and
penetratin (RQIKIWFQNRRMKWKK-NH2 ; net charge +8) were even more potent than TAT [12].
The high potency of R9 led us to explore other poly-arginine peptides (e.g., R1, R3, R6–R15, R18, R22),
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as well as several other CARPs, including protamine in the in vitro excitotoxic and OGD neuronal
injury models [27–29]. These studies confirmed that CARPs are highly neuroprotective, with efficacy
increasing with arginine content and peptide positive charge; peaking at R15 to R18 for poly-arginine
peptides [27,29] [Note arginine and lysine (K) are the only positively charged amino acids, while
histidine has a low positive charge].
Our laboratory has also demonstrated that CARPs and in particular the poly-arginine
peptide R18 are neuroprotective in in vivo experimental brain ischemic and/or hypoxic injury
models [18,20–22,24,26,27,29], and that CARPs can reduce neuronal cell surface glutamate receptor
levels and excitotoxic calcium influx [19,22,23,25,27,28]. As highlighted previously [19], based on
our findings, we have proposed that the neuroprotective properties of most, if not all, putative
neuroprotective peptides fused to cationic CPPs (e.g., TAT, R9 and penetratin), as well as other CARPs,
are determined by the arginine content and positive charge of the peptide, with potency also influenced
by other amino acid residues (e.g., lysine, tryptophan and phenylalanine) [19,29]. Importantly,
an arginine and cationic charge mediated neuroprotective mechanism of action of CARPs, including
CPP-fused to putative neuroprotective peptides (e.g., TAT-NR2B9c and TAT-NR2Bct), is supported in
studies by Marshall et al. [65] and more recently McQueen et al. [66]. Based on studies from our own
and other laboratories, we believe that the mechanism of action of putative neuroprotective peptides
fused to a CPP need to be critically re-evaluated. In light of the potentially confounding effects of CPPs
and/or peptide arginine content and positive charge, we will review studies using neuroprotective
peptides in HIE models. First, we provide a summary of the known and potential neuroprotective
actions of CARPs.
4.3. Cationic Arginine-Rich Cell-Penetrating Peptide Neuroprotective Mechanisms of Actions
While the exact mechanisms of the neuroprotective effects are still being explored, we and
others have demonstrated that CARPs have multiple, potentially simultaneous mechanisms of action.
CARPs and putative neuroprotective peptides fused to cationic arginine-rich CPPs (i.e., TAT or R9;
e.g., JNKI-1-TATD, TAT-NR2B9c/NA-1, TAT-CBD3/R9-CBD3-A6K and TAT-3.2-III-IV) can mitigate
excitotoxic or potassium evoked neuronal intracellular calcium influx [19,27,67–69]. One mechanism
whereby CARPs have the capacity to reduce intracellular calcium influx is the reduction of neuronal
cell surface ion channels and receptors; thereby reducing excitotoxic calcium influx. To this end,
CARPs have been demonstrated to reduce the cell surface expression or function of neuronal
NMDA receptors [23,63,70–73], voltage gated calcium channels (CaV2.2 and CaV3.3) [68,70,74,75],
a voltage gated sodium channel (NaV1.7) [76] and the sodium calcium exchanger 3 (NCX3) [70].
Given their effects on different receptors, and the positive charge of CARPs, they may also be
antagonizing ion channel receptor function directly and/or by affecting calcium or sodium ion influx
via an electrostatic mechanism.
In addition to neuronal cell surface receptor interactions, CARPs may also exert pleiotropic
neuroprotective effects by targeting mitochondria and maintaining mitochondrial integrity by reducing
calcium influx into the organelle [65,77–83]. CARPs have the capacity to inhibit proteolytic enzymes
including the proteasome [84,85], as well as pro-protein convertases [86–88] that activate MMPs [89].
Inhibition of the proteasome is known to be beneficial following cerebral ischemia [90–92]; a mechanism
that could be mediated by increased activity of hypoxia-inducible factor 1-α (HIF1α) and decreased
activity of nuclear factor κ-light-chain-enhancer of B cells (NFκB). Similarly, MMP activation in the
brain is known to be detrimental following cerebral ischemia and inhibiting MMP activation is
neuroprotective (see review Cunningham et al. [93]).
Furthermore, there is also evidence that CARPs activate pro-survival signaling pathways [67,94],
modulate immune responses [95–97] and act as anti-oxidant molecules in their own right due to their
guanidine group in arginine residues [65,83,98–101].
Interestingly, the neuroprotective potency of CARPs appears to correlate with the same
characteristic that improve the ability of cationic CPPs to target and transverse cellular membranes [19,29].
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This suggests that CARP-mediated neuroprotection is associated with cellular membrane interactions
(e.g., plasma and mitochondrial), anionic structures (phospholipids/cardiolipin, heparan sulfate
proteoglycans, chondroitin sulfate proteoglycans, sialic acid resides, anionic regions of surface
receptors) and/or increased levels of cellular uptake, which enable the peptides to interact with
membrane (e.g., ion channel receptors) and intracellular targets (e.g., proteins, ROS and mitochondria).
4.4. Studies Using CARPs in Animal Models of HIE
All descriptive details of the studies discussed below are presented in chronological order of
publication (Table 1).
4.4.1. TAT-NEMO Binding Domain (NBD)
NEMO binding domain (NBD) is an 11-amino acid peptide (NBD: TALDWSWLQTE735–745; net
charge −2) derived from the Nuclear Factor-κβ (NF-κβ) Essential Modulator (NEMO)/IKK-γ-Binding
Domain. The NBD peptide was designed to inhibit the activation of NFκB, a transcription factor
involved in many stress responses. For example, NBD was originally developed to suppress
inflammatory responses (e.g., IL-6, iNOS, MMP-9 and COX-2) and the regulation of apoptotic
Bcl proteins (e.g., Bcl-2 and Bcl-x) following cytokine stimulation in several disorders including
inflammatory bowel disease, arthritis, type I diabetes, multiple sclerosis and Parkinson’s disease [102].
Activation of NF-κB requires upstream kinase complex formation (IκB-kinase; IKK) composed of the
IKKα, IKKβ and NEMO proteins. For NF-κB activation, NEMO interacts with a carboxyl terminal
sequence within both IKK-α and IKK-β, known as the NBD. The NBD peptide inhibits NF-κB activation
by blocking NEMO/IKK complex formation [103].
The first study examining the neuroprotective efficacy of the NBD peptide in a model of
HIE (P12 rat) administered the peptide [(14,820 nmol/kg: intraperitoneally (IP)] immediately,
6 and 12 h after hypoxia and did not demonstrate any neuroprotection; instead NBD appeared
to increase brain injury [104]. To improve delivery to the brain, the NBD peptide was fused
to TAT (TAT-NBD: YGRKKRRQRRR-TALDWSWLQTE; net charge +6) and assessed in a P7 rat
model of HIE [105], where administration (6917 nmol/kg: IP) immediately and 3 h, or as a single
injection at 0, 3 or 6 h, after hypoxia was neuroprotective up to 6 weeks post-HI. When TAT-NBD
was administered immediately and 3 h after hypoxia it prevented up-regulation of p53 and
activation of caspase-3 24 h post-HI. TAT-NBD treatment also prevented the activation of IKK in
the brain 3 h post-HI. Despite TAT-NBD inhibiting IKK and NF-κB activation, it had no effect on
HI-induced increases in cytokines (e.g., IL-1β, TNF-α, IL-4, IL-10 and IL-1-RA). The study also
assessed a TAT-NBD control peptide, where two tryptophan residues were substituted for two
alanine residues (YGRKKKRRQRRR-TALDASALQTE; net charge +6) and was shown not to be
neuroprotective. Further assessment of TAT-NBD (6817 nmol/kg: IP) involving administration
immediately and 3 h, immediately, 3, 6 and 12 h, immediately, 6 and 12 h, as well as 18 and 21 h
after hypoxia [106], revealed long-term neuroprotection only in animals treated immediately and 3 h
post-HI. Concomitantly, TAT-NBD treatment immediately and 3 h after hypoxia significantly reduced
HI-mediated cytokine levels, whereas immediate, 3, 6 and 12-h treatment did not reduce cytokines.
In a subsequent study, TAT-NBD treatment (6818 nmol/kg: IP) immediately and 3 h after hypoxia
demonstrated significant improvements in behavioral outcomes up to 14 weeks post-HI [107].
Since intrauterine infections can be associated with HIE, TAT-NBD was assessed in a
lipopolysaccharide (LPS)-sensitized (IP injection) HIE model in the P7 rat [108]. Animals were
administered with TAT-NBD (477 nmol/kg) intranasally (IN) 10 min after hypoxia, using three HI
injury conditions; HI only, 4-h LPS-pre-treatment + HI or 72-h LPS-pre-treatment + HI. Treatment with
TAT-NBD significantly reduced brain injury only in the LPS-sensitized HI models, when assessed 7
days post-HI. While it was surprising that TAT-NBD did not reduce brain injury following HI only,
its neuroprotective actions in LPS-sensitized HI models may be due to the ability of the cationic
TAT-NBD peptide to electrostatically bind and neutralize anionic LPS molecules or by reducing the
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effects of inflammatory cytokines. Neutralizing LPS would have the effect of suppressing the molecules
capacity to evoke an immune response and inflammatory response. In support of this mechanism,
previous studies using in vitro cell and in vivo tissue injury models have demonstrated that CARPs
(e.g., HBD-2, HNP-1 and indolicidin) can bind to LPS and reduce its inflammatory effects [109].
Furthermore, it is possible that the IN delivery of TAT-NBD was enough to reduce the detrimental
effects of LPS, but not ischemic injury associated with HI.
4.4.2. TAT-mGluR1
mGluR1 is a 14-amino acid peptide (mGluR1: VIKPLTKSYQGSGK929–942 ; net charge +3),
corresponding to an intracellular region of the metabotropic glutamate receptor-1α (mGluR1α) protein
that is cleaved by calpain in neurons following excitotoxicity [110]. It is proposed that TAT-mGluR1
(YGRKKRRQRRR-VIKPLTKSYQGSGK, net charge +11) blocks the ability of calpain to cleave
mGluR1α and thus maintain the receptors ability to stimulate the neuroprotective phosphoinositide
3-kinase/protein kinase B (PI3K-Akt) signaling pathway and protect neurons from the toxic effects
of excitotoxic calcium influx [110]. In a neuronal model of kainic acid mediated excitotoxicity,
TAT-mGluR1 prevented mGluR1α truncation and reduced neuronal cell death [110]. In a P7 rat
model of HIE [111] TAT-mGluR1 (58,590 nmol/kg; IP) administered 1 h before hypoxia significantly
reduced cerebral infarction at 24 h post-HI.
4.4.3. c-Jun N-Terminal Kinase (JNK) Inhibitors
JNKI-1 is a 20-amino acid peptide (also referred to as JBD: RPKRPTTLNLFPQVPRSQDT157–176 ;
net charge +3), derived from the signaling adaptor protein c-Jun N-terminal kinase protein-1
(JNKI-1) [112]. JNKs are a member of the mitogen-activated protein kinases (MAPK) family,
encoded by the Jnk1, Jnk2 and Jnk3 genes, with high expression levels in neurons, especially
after pathological injury (e.g., excitotoxicity, stroke, epilepsy and HI) [113]. The JNKI-1 peptide
can inhibit JNK interaction with JNK-interacting protein-1 (JIP-1), blocking JNK phosphorylation
and activation, thereby inhibiting downstream pro-death cellular signaling pathways [112].
JNK has emerged as a central mediator of excitotoxic damage in the developing [114,115] and
developed CNS [116,117]. The JNKI-1 peptide derivatives bound to TAT, such as TAT-JNKI-1L
(YGRKKRRQRRR-PP-RPKRPTTLNLFPQVPRSQDT-NH2 , net charge +12) and its retro inverso
D-enantiomer JNKI-1-TATD (tdqsrpvqpflnlttprkpr-pp-rrrqrrkkrgy-NH2 ; net charge +12, lower
case indicates D-isoform amino acids) have demonstrated in vitro and/or in vivo neuroprotective
properties. Studies using the JNKI-1 peptide alone (D-JNKI-1) or when fused to TAT (TAT-JNKI-1L
and JNKI-1-TATD) have been assessed in neonatal HIE models.
The initial study examining the efficacy of D-JNKI-1 (tdqsrpvqpflnlttprkpr-NH2 ; net charge +4) in
a P7 rat model of HIE when administered (76 nmol/kg: IP) 30 min before and 3, 5, 8, 12 and 20 h after
hypoxia did not reveal any reduction in cerebral infarction at 24 h [115], although there was evidence
for reduced calpain, caspase-3 and autophagic activation.
A subsequent study demonstrated that the TAT-fused peptide JNKI-1-TATL administered
(2446 nmol/kg; IP) immediately and 3 h or 3 h after hypoxia, significantly reduced cerebral infarction
at 48 h, while administration 6 h after hypoxia was ineffective [118]. When administered immediately
and 3 h after hypoxia, functional benefits were observed 14 weeks post-HI. Despite improvements in
cerebral infarct and functional outcomes, JNKI-1-TATL failed to prevent caspase-8-mediated cleavage
of Bid, which was unexpected, as activated JNK is known to induce caspase-8 cleavage of Bid and
promote mitochondrial pro-apoptotic cell death pathways; this suggests JNKI-1-TATL-mediated
neuroprotection was occurring via mechanism independent of JNK suppression.
In a second study, the D -isoform peptide JNKI-1-TATD (2616 nmol/kg: IP) significantly reduced
cerebral infarct volume when administered immediately, 3 or 6 h after hypoxia, but not when
administered immediately and 3 h after hypoxia [119]. JNKI-1-TATD treatment also provided long-term
functional improvements. It was also demonstrated that treatment with JNKI-1-TATD reduced
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mitochondrial levels of phosphorylated JNK, preserved mitochondrial integrity, and up-regulated
anti-apoptotic proteins 24 h post-HI. The study also assessed a mitochondrial JNK scaffold
inhibiting peptide, SabKIM1 (gfeslsvpspldlsgprvva-pp-rrrqrrkkrg; net charge +7) and a scrambled
control (lpsvfgdvgapsrlpevsls-pp-rrrqrrkkrg; net charge +7); Sab (SH3 domain-binding protein 5) is
a mitochondrial scaffold protein required for JNK kinase activity. Administration of SabKIM1 (2700 and
5555 nmol/kg: IP) immediately after hypoxia was neuroprotective, whereas the scrambled peptide
(2700 nmol/kg: IP) was ineffective.
In our laboratory, administration of JNKI-1-TATD (1000 nmol/kg; IP) immediately after hypoxia
resulted in a positive trend in reduced total infarct volume (15% reduction) although it did not
improve behavioral outcomes 48 h post-HI [22]. It was also demonstrated that in cultured cortical
neurons JNKI-1-TATD dose-dependently reduced glutamic acid mediated excitotoxic intracellular
calcium influx.
While it was surprising that the SabKIM1 scrambled control peptide did not display any
neuroprotection, it is possible that the amino acid sequence of the cargo peptide may have
influenced neuroprotective potency. Importantly, we and others have confirmed that TAT-fused
scrambled peptides such as TAT-p53DMs and TAT-NR2cts [29,66] still retain neuroprotective
properties, again pointing to an active role of the TAT carrier and peptide arginine content mediated
neuroprotective action.
4.4.4. TAT-BH4
BH4 is a 25-amino acid peptide derived from the Bcl-x(L) protein BH4 homology domain region
(RTGYDNREIVMKYIHYKLSQRGYEW6–30 , net charge +2.1). The BH4 domain is required by Bcl-x(L)
to block cytochrome-c release from mitochondria and prevent MPTP opening [120], as well as inhibiting
endoplasmic reticulum (ER) calcium release into the cytosol by binding to a regulatory domain of
the inositol triphosphate-3 (IP3) receptor [121]; highlighting potential mechanisms whereby the BH4
peptide could exert a neuroprotective action after HI.
The TAT-BH4 (YGRKKRRQRRR-RTGYDNREIVMKYIHYKLSQRGYEW, net charge +10.1) peptide
was demonstrated to reduce cerebral tissue damage and caspase-3 activation when administered
intracerebroventricularlly (ICV; 5 µL/20 ng) 30 min before hypoxia in a P7 rat model of HI [122].
Interestingly, exposure of cultured adult neural stem cells to TAT-BH4 promoted axonal remodeling,
suggesting the peptide exerts other effects that may be beneficial in improving recovery following HI.
4.4.5. Osteopontin (OPN) and TAT-Fused OPN Peptide (TAT-OPN)
Osteopontin (OPN) is a secreted acidic glycoprotein containing an arginine-glycine-aspartate
(RGD) motif and possesses multiple cellular functions including chemotactic and cytokine-like actions.
The OPN protein is expressed in various tissues including bone, placenta, pancreas and the CNS [123].
Following cerebral ischemia, OPN deficient mice demonstrate increased neurodegeneration [124] and
when administered ICV, the protein is neuroprotective in several adult rodent cerebral ischemia and
hemorrhagic stroke models [125–128].
Mechanisms thought to be associated with OPN-mediated neuroprotection include binding
to the cell surface αvβ3 integrin receptor to stimulate pro-survival signaling (i.e., PI3K/Akt
pathway), anti-inflammatory effects [126,129–131], inhibition of inducible NOS [132,133] STAT1
ubiquitination/degradation and by reducing MMP-9 and NF-κβ activation. Despite OPN’s
demonstrated neuroprotective effects, in one study OPN deficient mice demonstrated no change
in susceptibility to ischemic brain injury [126].
The first study to examine the neuroprotective efficacy of OPN in HIE used full length recombinant
OPN protein (rOPN) in a P7 rat model of HI [134]. Animals treated with rOPN (0.03 or 0.1 µg per animal:
ICV) 60 min after hypoxia, displayed a reduction in infarct volume at 48 h and significant improvements
in behavioral outcomes at 7 weeks post-HI. In contrast, treatment with rOPN (0.05 µg/animal: ICV
or 1.2 µg/animal: IN) or thrombin cleaved rOPN (1.2 µg/animal: IN) was not neuroprotective in
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a P5 mouse model of HI [135]. To improve cerebral delivery of OPN, a shorter peptide containing the
RGD motif (IVPTVDVPNGRGDSLAYGLR134–153 ; net charge 0) was developed. However, the shorter
peptide was not neuroprotective when administered ICV (0.2 µg/animal) or IN (30 µg/animal) before
hypoxia in P5 mice [135]. In a subsequent study the OPN134–153 peptide was fused to TAT (TAT-OPN;
YGRKKRRQRRR-IVPTVDVPNGRGDSLAYGLR, net charge +8) and assessed in a P9 mouse model of
HI [136] using several peptide treatment regimens consisting of multiple dosing using IN, IP or ICV
administration (see Table 1 for details). No treatment regimen reduced infarct volume or improved
functional assessments up to 35 days post-HI. Taken together, current evidence indicates that at the
dosing schedules examined for the TAT-OPN peptide, it is not neuroprotective in HIE rodent models.
4.4.6. P5-TAT
P5 is a 24-amino acid peptide derived from the C-terminal region of the p35 protein
(KEAFWDRCLSVINLMSSKMLQINA254–277 , net charge +0.9). Following cleavage of p35 by calpain,
a cleavage fragment known as p25 can bind to cyclin-dependent kinase 5 (Cdk5) and alter its
cellular location and stimulate its activity [137], which is known to be associated with neuronal
cell death [138–140]. Administration (3,660, 7,320 and 9,761 nmol/kg: IP) of a modified P5 peptide
(TFP5: KEAFWDRCLSVINLMSSKMLQINAYARAARRAARR; net charge +5.9) can improve outcomes
in Parkinson’s disease, Alzheimer’s disease, and adult ischemic stroke models in rodents [140–142].
A dose-response assessment (0.23, 2.30, 5.76 and 11.5 nmol/kg; IP) of P5-TAT
(KEAFWDRCLSVINLMSSKMLQINA-YGRKKRRQRRR, net charge +8.9) when administered 30 min
before hypoxia in P7 rats demonstrated that all doses, except 0.23 nmol/kg, significantly reduced
cerebral infarct volume at 48 h [143]. In addition, P5-TAT, when administered (11.5 nmol/kg; IP) 24 h
after hypoxia, significantly improved behavioral outcomes up to 3 weeks post-HI. However, P5-TAT
treatment following HI did not have any effect on the levels of Cdk5 activators, p35, p25 or p29, despite
suppressing cleavage of caspase-3.
4.4.7. D-TAT-GESV
GESV is a 4-amino acid peptide (GESV, net charge −1) derived from the carboxyterminal PDZ
motif (PDZ-G(D/E)XV; net charge −1) of nNOS. Proteins containing PDZ domains play a key role in
anchoring receptor proteins in the membrane to intracellular cytoskeletal structures (e.g., actin and
microtubules) and cytosolic proteins. Following NMDA receptor stimulation, nitric oxide synthase-1
adaptor protein (NOS1AP) via its PDZ binding domain, binds nNOS and recruits the protein to the
cell membrane where it generates nitric oxide (NO). The D-TAT-GESV peptide (ygrkkrrqrrr-GESV,
net charge +7) inhibits NOS1AP/nNOS binding, and is believed to confer neuroprotection by reducing
NO production and activation of the p38 MAPK stress pathway [144]. In a P7 rat model of HIE,
D-TAT-GESV (100 ng: ICV), administered before hypoxia reduced cerebral infarction at 7 days
post-HI [145]. In comparison, the control peptide D-TAT-GASA (100 ng: ICV) was ineffective [145],
which is not surprising since alanine residues can reduce CARP neuroprotective efficacy [19].
4.4.8. TAT-NR2B9c/NA-1
The development of NR2B9c as a neuroprotective agent has recently been discussed in detail [146].
Briefly, NR2B9c is a 9 amino acid peptide (KLSSIESDV1479–1487 ) derived from the intracellular terminal
carboxyl region of the NMDA receptor NR2B subunit protein, a site that binds the adaptor protein
postsynaptic density-95 (PSD-95). PSD-95 couples nNOS to the NR2B subunit and following NMDA
receptor activation stimulates NO generation. The NR2B9c peptide was developed on the basis that it
blocks NR2B subunit and PSD-95 binding and thereby inhibiting NO production following NMDA
receptor stimulation.
TAT-NR2B9c (YGRKKRRQRRR-KLSSIESDV; net charge +7) administered (19,850 nmol/kg; IP)
either 110 min or 20 min before hypoxia in mice reduced brain injury at 24 h post-HI [147]. In addition,
TAT-NR2B9c treatment significantly improved behavioral outcomes up to 7 days after HI. Interestingly,
a 3000 nmol/kg dose (IP), administered 20 min before hypoxia was ineffective.
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4.4.9. Poly-Arginine-18 (R18 and R18D)
R18 (RRRRRRRRRRRRRRRRRR; net charge +18) and its D-enantiomer (rrrrrrrrrrrrrrrrrr; net
charge +18) is an 18-amino acid peptide and has been demonstrated to have potent neuroprotective
properties in various in vitro and in vivo stroke related injury models [18,24,26,29]. Moreover, we
have recently demonstrated for the first time that R18 and R18D (30, 100, 300 and 1000 nmol/kg; IP),
administered immediately after hypoxia, reduced cerebral infarct volume and improved behavioral
outcomes at 48 h post-HI [22]. In an additional study, administration of R18D 30 (10, 30, 300
and 1000 nmol/kg; IP) and 60 min (30 nmol/kg; IP) after hypoxia, reduced cerebral infarct volume
and improved behavioral outcomes at 48 h post-HI [21].
4.5. Other Peptides Examined in Animal Models of HIE
Several other peptides, not fused to a CPP, have also been examined in animal models of HIE.
All descriptive details of the studies discussed below are presented in chronological order of publication
and in Table 1.
4.5.1. COG133
COG133 is a 20-amino acid peptide (TEELRVRLASHLRKLRKRLL133–152 , net charge +5.1) derived
from the apolipoprotein E (apoE) protein. COG133 has been demonstrated to be neuroprotective
in several acute brain injury models and demonstrated to possess anti-oxidant, anti-excitotoxic and
anti-inflammatory properties [148–152]. Exactly how the COG133 peptide imparts its anti-oxidant,
anti-excitotoxic and anti-inflammatory properties is not known, but the positive charge of the peptide
has been considered as a critical factor [19,148]. When examined in a P7 rat model of HIE, COG133
administration (40, 200, 300, 400 and 2000 nmol/kg: ICV) immediately before hypoxia displayed
a neuroprotective dose-response effect [151].
4.5.2. Connexin 43 (Cx43) Derived Peptides
Astrocytic gap junction hemichannels play an essential role in the regulation of electrolytes
and metabolites between the cytosol and extracellular space. Under physiological conditions,
hemichannels are usually in a closed state. Specifically, connexin 43 (Cx43) hemichannel opening occurs
following hypoxia, ischemia and OGD [153–156], resulting in a disruption to cellular homeostasis and
an exacerbation of excitotoxicity [157]. The non-specific blocking of gap junction hemichannels with
octanol and carbenoxolone demonstrates neuroprotective effects in in vitro models of hippocampal
hypoxic-hypoglycemic injury [158,159]. To overcome the non-specific blocking of gap junction
hemichannels, small mimetic peptides that bind to the extracellular loop of Cx43 hemichannels,
blocking hemichannel opening have been developed [160].
Several studies have assessed the administration of a Cx43 mimetic peptide (Peptide 5:
VDKFLSRPTEKT, net charge +1) in fetal sheep models of HIE. Administration of Peptide 5 continuously
for either 1 (50,000 nmol/kg/h; ICV) or 25 h (50,000 nmol/kg over 1 h and then over 24 h; ICV),
beginning 90 min after hypoxia, improved electroencephalographic (EEG) recovery, reduced seizure
activity and improved the return of sleep state cycling. In addition, the 25-h infusion of Peptide 5
improved oligodendrocyte survival at 7 days post-HI [161]. Another study demonstrated Peptide 5
administration immediately after hypoxia (50,000 nmol/kg over 1 h and then over 24 h; ICV) improved
neuronal and oligodendrocyte cell survival, whereas peptide administration beginning during hypoxia
(50,000 nmol/kg for 1 h and then for 24 h; ICV) was not neuroprotective [162]. In contrast, a continuous
high dose infusion of Peptide 5 (50,000 nmol/kg/h over 25 h: ICV) immediately after hypoxia did not
improve neurological outcome and contributed to cerebral edema in the fetal sheep 7 days post-HI [163].
In a pre-term (103 days gestation) fetal sheep model of HI, Peptide 5 administration (50,000 nmol/kg
for 1 h and then for 24 h; ICV) commencing 90 min after hypoxia improved EEG recovery, reduced
neuronal death and increased oligodendrocyte cell survival 7 days post-HI [164]. A study using
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term fetal sheep assessed Peptide 5 and hypothermia (32 ± 1 ◦ C; 72 h), as individual treatments and
when combined. Peptide 5 administration 3 h after hypoxia (50,000 nmol/kg for 1 h and then for
24 h; ICV) and hypothermia treatments alone, improved EEG power, neuronal and oligodendrocyte
cell survival at 7 days post-HI. However, combined Peptide 5 and hypothermia treatment did not
result in any additional improvement in EEG power or histological outcomes [165]. This suggests that
neuroprotective targets, other than hemichannels, may be more appropriate to improve the therapeutic
effects of hypothermia for HIE.
Other Cx43 mimetic peptides (Gap 26: VCYDKSFPISHVR; net charge +1 and Gap 27: SRPTEKTIFII;
net charge +1) have demonstrated neuroprotective efficacy in a P7 rat model of HIE [166]. Gap 26 (0.64,
3.22, 6.44, 16.1 and 32.2 nmol/kg; IP) and Gap 27 (16.1 nmol/kg; IP) administered 1 h before hypoxia,
reduced infarct volume at 48 h post-HI; however, the two lower doses of Gap 26 were ineffective.
In addition, multiple administrations of Gap 26 (32.2 nmol/kg: IP) every day for 7 days, beginning
24 h after hypoxia reduced brain injury and improved neurological function, up to 3 weeks post-HI.
Since Cx43 mimetic peptides Peptide 5, Gap26 and Gap 27 have only one arginine residue and low
cationic charge, it would seem unlikely the peptides are operating via a CARP mechanism of action.
4.5.3. Apelin-36
Apelin is an endogenous ligand of the apelin receptor, a G protein-coupled receptor,
which is widely expressed throughout the body, including neurons and oligodendrocytes [167].
The human APELIN gene encodes a 77 amino acid pre-protein, that is cleaved into at least three
biologically active fragments, Apelin-13(65–77) , Apelin-17(61–77) and Apelin-36(42–77) . The active apelin
fragments are widely expressed in the body including the CNS [168]. Apelin peptides have been
demonstrated to reduce neuronal excitotoxicity and activate extracellular signal-regulated kinase
1/2 ERK-1/2 and PI3K/Akt cell survival pathways in cultured neurons [169–171]. Apelin-36
(LVQPRGSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF42–77 ; net charge +10.1) has been assessed
in a P7 rat model of HIE [172] with administration (1000 ng: IP) 1 h before hypoxia reduced infarct
volume at 48 h post-HI, and improving neurological function up to 14 days post-HI.
4.5.4. Innate Defense Regulator (IDR) Peptide IDR-1018
Innate defense regulator (IDR) peptides are endogenous cationic host defense peptides [173,174].
IDRs modulate inflammatory responses by increasing the recruitment of immune cells to sites
of infection and inflammation; increasing wound-healing properties. It is believed that IDRs
reduce cerebral injury following HI by reducing the impact of damaging inflammatory responses.
IDR-1018 (VRLIVAVRIWRR-NH2 ; net charge +5) is a synthetic host defense peptide examined in
an LPS-sensitized model of HIE in P9 mice [175]. IDR-1018 administered (5208 nmol/kg: IP) 4 h
before hypoxia reduced brain injury-related gene pathways that include p53 activation and calcium
signaling. In addition, IDR-1018 administered (5208 nmol/kg: IP) 3 h after hypoxia, reduced infarct
and inflammatory mediators (e.g., TNF-α, IL-1β, IL-4, IL-6, IL-10, IL-17, keratinocyte chemoattractant,
INF-γ and granulocyte-macrophage colony stimulating factor) 8 days post-HI.
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Table 1. Studies using CARPs and other peptides examined in animal models of HIE.
Peptide/Protein Name;
Net Charge a

Proposed
Target b

Peptide Sequence c

Injury Model d

P7 (W): CCAO/8% O2; 120 min
TAT-NBD; +6

NFκB

Calpain

D-JNKI-1; +4
JNKI-1-TATL; +12
JNKI-1-TATD; +12

JIP

Dose

IP: 0 & 3 h, or 0, 3, 6, 9 or 12 h

NP f

Study

6917 nmol/kg

Yes, up to 6 h

[105]

IP: 0 & 3 h, or 0, 9 & 12 h, or 18 & 21 h

6817 nmol/kg

Yes, only for 0 &
3h

[106]

IP: 0 & 3 h

6818 nmol.kg

Yes

[107]

IN; 10 min

477 nmol/kg

Yes, only for LPS

[108]

TAT-TALDWSWLQTE
P7 (W): CCAO/10% O2; 90 min
+ LPS 4 or 72 h before hypoxia

TAT-mGluR1; +3

Route & Time before/after HI
Agent Administered e

TAT-VIKPLTKSYQGSGK

P7 (SD): CCAO/8% O2; 150 min

IP: −1 h

58,590 nmol/kg

Yes

[111]

tdqsrpvqpflnlttprkpr-NH2

P7 (SD): CCAO/8% O2; 120 min

IP, −0.5, 3, 5, 8, 12 and 20 h

76 nmol/kg

No

[115]

TAT-PPRPKRPTTLNLFPQVPRSQDT-NH2

P7 (W): CCAO/8% O2; 120 min

IP: 0 and 3 h, or 3 h or 6 h

2446 nmol/kg

Yes, except 6 h

[118]

IP: 0, 3 or 6 h, or 0 & 3 h

2616 nmol/kg

[119]

IP: 0 h

2777 or 5555 nmol/kg

Yes except
0&3h
Yes

tdqsrpvqpflnlttprkpr-pp-tat-NH2
P7 (W): CCAO/8% O2; 120 min
lpsvfgdvgapsrlpevsls-pp-tat

SabKIM1 +7
JNKI-1-TATD; +12
TAT-BH4; +2.1

Apoptosis

P7 (SD): ECA/CCAO/8% O2; 150 min

IP: 0 min

1000 nmol/kg

No

[22]

P7 (SD♂): CCAO/8% O2; 150 min

ICV: −0.5 h

5 µL/20 ng

Yes

[122]

IN: −70 min

1.2 µg
IN: 30 µg/ICV: 0.2 µg

No

[135]

No

[136]

Yes, except
0.23 nmol/kg

[143]

Thrombin cleaved OPN

T-OPN

IVPTVDVPNGRGDSLAYR

OPN134–153 ; 0
OPN154–198 ; −4.9

tdqsrpvqpflnlttprkpr-pp-tat-NH2
TAT-RTGYDNREIVMKYIHYKLSQRGYEW

αv β3 integrin
receptor

TAT-OPN; +8

P5 (C57B6/6J): CCAO/10% O2; 70 min

IN or ICV: −70 min

SKSRSFQVSDEQYPDATDEDLTSHMKSGES
KESLDVIPVAQLLSM

ICV: −70 min

0.5 µg

TAT-IVPTVDVPNGRGDSLAYGLR

P9 (C57BL/6N): CCAO/10% O2; 50 min

IN: 0 h or 0 & 3 h, or 0, 3 h, 1, 2 & 3 d
IP: 0 h, or 5, 7, 9, 11, 13, 15 d, or 0, 1, 3,
5, 7, 9, 11, 13, 15 d
ICV: 1 h

350 or 2100 ng
2746 nmol/kg

IP: −1 h
IP: 24 h

0.23, 2.3, 5.76, or 11.5 nmol/kg
11.5 nmol/kg

100 ng

P35

KEAFWDRCLSVINLMSSKMLQINA-TAT

P7 (SD): CCAO/8% O2; 150 min

D-TAT-GESV; +7

NOS

ygrkkrrqrrr-GESV

P7 (SD♂); CCAO/8% O2; 120 min

ICV: −120 min

100 ng/animal

Yes

[145]

TAT-NR2B9c; +7

PSD-95

TAT-KLSSIESDV

P7 (CD1): CCAO/7.5%; 60 min

IP: −110 or −20 min

3000 nmol/kg

Yes

[147]

IP: 0 h

30, 100, 300 or 1000 nmol/kg

Yes

[22]

IP: +0.5 h
IP: +1 h
IP: +1.5 h

10, 30, 100, 300 or 1000 nmol/kg
30 or 300 nmol/kg
30 or 300 nmol/kg

Yes, except
100 nmol/kg
Yes, except
300 nmol/kg
No

[21]

ICV: −0 h

40, 200, 300, 400, or 2000 nmol/kg

Yes, except
300 nmol/kg

[151]

P5-TAT; +8.9

RRRRRRRRRRRRRRRRRR
rrrrrrrrrrrrrrrrrr

R18; +18
R18D; +18
Multiple

rrrrrrrrrrrrrrrrrr

R18D; +18

COG133; 5.1

P7 (SD): ECA/CCAO/8% O2; 150 min

LDLR

Ac-TEELRVRLASHLRKLRKRLL-NH2

P7 (W): CCAO/8% O2; 150 min

Brain Sci. 2018, 8, 147

14 of 26

Table 1. Cont.
Peptide/Protein Name;
Net Charge a

Proposed
Target b

Peptide 5; +1

Peptide Sequence c

VDKFLSRPTEKT

Injury Model d

GD103 (Romney/Suffolk sheep):
bilateral tCCAO for 25 min
VCYDKSFPISHVR

Gap 27; +1

SRPTEKTIFII

P7 (SD): CCAO/8% O2; 150 min

Apelin-36; +10.1

Apelin
receptor

IDR-1018; +5

Immune
modulation

ICV: 1.5 h

NP f

Study

50,000 nmol/kg/h for 1 h ±
50,000 nmol/kg/24 h for 24 h

Yes

[161]

ICV: −1 h or 0 h

50,000 nmol/kg/h: 1 h +
50,000 nmol/kg/24 h for 24 h

Yes, except
−1 h

[162]

ICV: 0 h

50,000 nmol/kg/h: 1 h +
50,000 nmol/kg/24 h for 24 h
50,000 nmol/kg/h for 25 h

Yes, except high
continuous dose

[163]

ICV: 3 h ± Hypothermia: 32 ◦ C for
72 h; 3 h after tCCAO

50,000 nmol/kg/h for 1 h +
50,000 nmol/kg/24 h for 24 h

Yes, no additive
effect

[165]

ICV: 1.5 h

50,000 nmol/kg/h for 1 h +
50,000 nmol/kg/24 h for 24 h

Yes

[164]

IP: −1 h
IP: daily for 1 to 7 d

0.64, 3.22, 6.44, 16.1, or
32.2 nmol/kg
32.2 nmol/kg

Yes, except 0.64
and 3.22 nmol/kg

IP: −1 h

LVQPRGSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF
P7 (SD): CCAO8% O2; 150 min
VRLIVAVRIWRR-NH2

Dose

GD128 (Romney/Suffolk sheep):
bilateral tCCAO; 30 min

Cx43 astrocytic
hemichannel

Gap 26; +1

Route & Time before/after HI
Agent Administered e

P9 (C57BL/6J): CCAO/10% O2; 20 min +
LPS 14 h before hypoxia

[166]

16.1 nmol/kg

Yes

IP: −1 h

240 nmol/kg

Yes

[172]

IP: −4 h or 3 h

5208 nmol/kg

Yes

[175]

Bold data indicates peptides used in studies. a Net charge at pH 7, MUT: mutant peptide, SCR: scrambled peptide. b NFκB: nuclear factor kappa-light-chain-enhancer of activated B
cells, JIP: c-Jun N-terminal kinase-interacting protein, NOS: nitric oxide synthase, PSD-95: postsynaptic density-95, LDLR: low-density lipoprotein receptor. c Peptides synthesized
using D-amino acids are represented in lowercase, TAT = GRKKRRQRRR. d W: Wistar, SD: Sprague-Dawley, C57B/6: C57 black 6, CD1: cluster of differentiation 1, CCAO: common
carotid artery occlusion, ECA: external carotid artery occlusion, tCCAO: transient common carotid artery occlusion, ♂= male, GD = gestational day. e IP: intraperitoneal, IN: intranasal,
ICV: intracerebroventricular, h: hours, min: minutes; negative (−) = treatment before hypoxia. f Neuroprotection and or positive effects.
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5. Do All CARPs Including TAT-Fused Peptides Share a Common Neuroprotective Mechanism
of Action?
Based on previous studies in our and other laboratories, examining the neuroprotective properties
of various CARPs, we view it highly likely that the neuroprotection demonstrated by the CARPs
described above (i.e., TAT-NBD, TAT-mGluR1, JNKI-1-TATL, JNKI-1-TATD, SabKIM1 , TAT-BH4, P5-TAT,
D-TAT-GESV, TAT-NR2B9c, R18, R18D, COG133, Apelin-36 and IDR-1018) is largely mediated by
peptide arginine content and positive charge [19,27,29,65,66]. There are several lines of evidence
that support this hypothesis, which we provide below. In addition, we previously provided
an explanation why we believe a CARP-mediated neuroprotective mechanism of action is operating
for the TAT-NR2B9c and JNKI-1-TATD peptides, rather than the mechanism of action in which they
were originally developed [27].
It has been demonstrated that CARPs inhibit neuronal excitotoxic calcium [19,22,23,25,27,28] and
potassium [64,75] influx and in doing so inhibit many of the pathophysiological processes downstream
from the ischemic excitotoxic cascade (e.g., calpain activation, mitochondrial dysfunction and ROS
production, calcium induced cell signaling and lipase and DNase activation). Therefore, given that the
vast majority of the proposed mechanisms of action of developed TAT-fused and other neuroprotective
CARPs are molecular targets downstream from excitotoxicity (e.g., NF-κB, JNK and Cdk5), it is not
surprising that they are effective and appear to be inhibiting their intended targets.
Interestingly, in addition to the inhibition of excitotoxic cationic ion influx, CARPs also have
the capacity to modulate other cellular processes that are neuroprotective following HI such as
proteolytic enzyme activation (e.g., proteasome and MMPs), ERK-1/2 and Akt phosphorylation and
the modulation of immune responses. For example, in the case of TAT-NBD, which was developed to
block NF-κB activation, the ability of CARPs to inhibit the proteasome [84,85,176,177] would have the
effect of preventing NF-κB activation by preventing proteasomal degradation of the NF-κB inhibitor
protein i-κB.
In the case of Apelin-36, other CARPs, such as protamine and R9 (ALX40-4C) can also bind to the
apelin receptor [178,179]. Therefore, it is possible that CARPs, in addition to Apelin-36, may also be
able to stimulate pro-cell survival ERK-1/2 and Akt pathways [180]. Although it should be mentioned
that not surprisingly, Apelin-36 can also reduce excitotoxic calcium influx [169–171]. In the case of
CARP-mediated immune modulation, mR18L (Ac-GFRRFLGSWARIYRAFVG-NH2 ; net charge +4)
is known to reduce LPS-induced systemic infection [181], dRK6 (RRKRRR; net charge +6) inhibits
TNFα and IL-6 production by monocytes [182] and hBD3-3 (GKCSTRGRKCCRRKK; net charge +8)
downregulates NF-κB induced inflammation [183]. Thus, CARPs have the potential to suppress many
of the toxic inflammatory responses associated with HIE.
Future studies examining the efficacy of putative neuroprotective peptides fused to TAT would
benefit with respect to confirming neuroprotective mechanisms of action by fusing the peptide to
a non-cationic CPP (e.g., MTS; AAVALLPAVLLALLP) and/or replacing any negatively charged
aspartate (D) and glutamate (E) residues within the peptide sequence with arginine residues; we
predict these two manipulations will decrease and increase neuroprotective efficacy, respectively. It is
also advisable to confirm if the TAT-fused peptide has the capacity to reduce excitotoxic calcium influx.
6. Conclusions
There is now a large body of data from various sources demonstrating that CARPs comprise a class
of peptide with significant neuroprotective potential for development as an adjuvant to hypothermia,
or when hypothermia cannot be applied, for the treatment of HIE. While further studies are required
to elucidate neuroprotective mechanisms, available evidence indicates that CARP neuroprotection
is determined by the peptide’s arginine content and cationic charge and more specifically by the
guanidine head group in the arginine residues. Interestingly, CARP neuroprotective potency appears
to correlate with the same characteristics that improves the ability of the cationic CPPs to target and
traverse cellular membranes [19,29]. Taken together it is clear that CARPs possess many properties
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enabling them to target both intracellular and extracellular damaging and protective pathways that
are likely to be beneficial following HIE, not to mention their ability to cross the BBB and enter cells.
In conclusion, CARPs, including poly-arginine peptides, offer an exciting therapeutic approach for
HIE with the potential to reduce the severity of brain injury via potentially several neuroprotective
mechanisms of action.
7. Future Directions
There are several further considerations to be addressed before translation of CARPs as
a therapeutic for HIE in the clinic. It will be important to firstly identify a CARP that has high
efficacy and the greatest potential to be effective in HIE, in both pre-term and term infants. In addition,
preclinical studies will need to examine CARP treatment in combination with hypothermia to ensure
safety, and to identify any synergistic effects in terms of improving patient outcomes. It is also
important that beneficial results obtained in rodent models of HI, especially with combining CARPs and
hypothermia, are confirmed in a large animal model (e.g., piglet or lamb), allowing for assessment in
a gyrencephalic brain with greater comparability to the human and that the efficacy of IV administration
should be established prior to clinical trials.
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